Navigation Links
Bedford Laboratories(TM) to Begin Shipping Fluconazole Injection in PVC Flexible Containers
Date:4/13/2009

BEDFORD, Ohio, April 13 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the addition of Fluconazole injection 2 mg / mL in PVC flexible containers to its existing Fluconazole injection line. This product is AP rated and is equivalent to Diflucan(R) by Pfizer. Fluconazole injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is also indicated for the prophylaxis of candidiasis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product in PVC flexible containers. This product represents Bedford's entry into the I.V. bag market and demonstrates our ongoing commitment to providing a broad based portfolio of products," said David Gaugh, Vice President of Bedford Laboratories.

In addition to the glass vial presentations, Bedford Laboratories will supply Fluconazole injection as a sterile iso-osmotic solution containing 2mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations: 200mg / 100mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400mg / 200mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim Corporation

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Bedford Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Groundbreaking Research Begins for Pancreatic and Lung Cancers
2. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
3. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
4. Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients
5. Irvine Dermatologist Begins In-office Clinical Studies -- Nissan Pilest, MD Combines Multi-Use Botox in Laser Resurfacing Clinical Studies
6. First Seed Sales of Dedicated Energy Crops Begin
7. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
8. SemBioSys begins phase I/II trial of insulin produced in plant seeds
9. SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
10. Let the games begin! Nanosoccer at 2009 RoboCup in Austria
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... GREENWICH, Connecticut , November 30, 2016 ...   ... Aptuit, LLC today announced ... screening library. An additional 150,000 novel compounds have increased the ... selected to broaden the hit discovery capabilities of the company. ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... technology applications, introduces the 5th generation, ultra-bright, Laser-Driven Light Source, the EQ-77, at ... Source (LDLS™) technology, the EQ-77 offers higher radiance and irradiance from a truly ...
(Date:11/30/2016)... ... , ... With growth rates averaging more than 30% each year, Random42 has ... continuing their expansion in their new office space. The new office has a fantastic ... the creative industries, so Random42 Scientific Communication will fit right in. , Ben ...
(Date:11/30/2016)... November 30, 2016 Teil einer ... ... , Aptuit LLC ... zu haben. Zusätzliche 150.000 neuartige Substanzen haben die Prüfsammlung ... ausgewählt, um die starken Entdeckungsfähigkeiten des Unternehmens zu erweitern. ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):